Description
Generic Name:
Lamivudine + Tenofovir Disoproxil Fumarate + Dolutegravir
Composition:
Each Trilavir D PeP Tablet contains:
- Lamivudine (300mg): A nucleoside reverse transcriptase inhibitor (NRTI) that prevents the replication of HIV.
- Tenofovir Disoproxil Fumarate (300mg): An antiviral agent that blocks viral DNA synthesis, reducing viral load.
- Dolutegravir (50mg): An integrase inhibitor that prevents the HIV virus from integrating into human DNA, effectively stopping its spread.
- Excipients: [List of inactive ingredients like stabilizers, binders, and coatings].
Indication:
Trilavir D PeP Tablet is indicated for:
- Post-Exposure Prophylaxis (PeP): Used to reduce the risk of HIV infection after potential exposure through occupational or non-occupational means (e.g., needle-stick injuries, unprotected sex, or exposure to contaminated blood).
- HIV Management: Sometimes prescribed as part of an antiretroviral therapy (ART) regimen for HIV-positive individuals.
Storage Instructions:
- Store at room temperature (15-30°C) in a dry place.
- Keep away from direct sunlight, moisture, and heat.
- Store in its original packaging to protect from light.
- Keep out of reach of children and pets.
Uses of the Medicine:
- Post-Exposure Prophylaxis (PeP): Must be taken within 72 hours of potential HIV exposure to prevent infection.
- Combination Therapy: Used alongside other HIV medications for comprehensive treatment.
- Prevention of Viral Load Increase: Helps control viral replication in HIV-positive individuals.
Benefits of the Medicine:
- Effective HIV Prevention: Reduces the likelihood of HIV infection when taken correctly.
- Once-Daily Dosing: Enhances compliance and convenience.
- Strong Antiviral Action: Targets multiple stages of viral replication.
- Well-Tolerated: Minimal side effects in most patients.
Side Effects:
Common side effects may include:
- Nausea, vomiting, or diarrhea
- Headache or dizziness
- Fatigue or weakness
- Mild rash or skin irritation
- Insomnia or vivid dreams
Serious Side Effects Include:
Seek immediate medical attention if you experience:
- Severe allergic reactions (swelling of the face, lips, or throat, difficulty breathing).
- Liver toxicity (yellowing of skin/eyes, dark urine, abdominal pain).
- Kidney problems (reduced urine output, swelling in legs/feet).
- Mental health effects (severe depression, suicidal thoughts).
- Lactic acidosis (unexplained muscle pain, rapid breathing, drowsiness).
How to Use the Medicine:
- Take one tablet once daily, as prescribed by your doctor.
- Swallow whole with water; do not crush or chew.
- Can be taken with or without food.
- Must be taken consistently for 28 days for PeP effectiveness.
- Do not miss doses, as adherence is critical for effectiveness.
How the Medicine Works:
Trilavir D PeP Tablet works by blocking key steps in the HIV replication process:
- Lamivudine & Tenofovir: Prevent viral DNA formation by inhibiting reverse transcriptase.
- Dolutegravir: Stops the HIV virus from integrating into human DNA, preventing its spread.
What If You Forget to Take the Medicine?
- Take the missed dose as soon as possible.
- If it is almost time for your next dose, skip the missed dose.
- Do not take a double dose to make up for the missed one.
Quick Tips:
- Start PeP immediately after potential HIV exposure (preferably within 2 hours, but no later than 72 hours).
- Do not skip doses; adherence is crucial.
- Avoid alcohol and recreational drugs, which may worsen side effects.
- Use condoms and practice safe behaviors even while on PeP.
- Regular follow-up tests are required to confirm HIV-negative status.
Safety Advice

Alcohol
Caution is advised when consuming alcohol with Trilavir D Tablet. Please consult your doctor for guidance.
Pregnancy
Trilavir D Tablet is unsafe to use during pregnancy due to potential harm to the developing baby. It may only be prescribed in life-threatening situations where benefits outweigh the risks. Please consult your doctor.

Breastfeeding
There is insufficient information on the use of Trilavir D Tablet while breastfeeding. Please consult your doctor before use.

Driving
It is uncertain whether Trilavir D Tablet affects your ability to drive. Avoid driving if you experience drowsiness, dizziness, or reduced alertness.

Kidney
Limited data is available on the safety of Trilavir D Tablet in patients with kidney disease. Dose adjustments may be necessary. Please consult your doctor.

Liver
Trilavir D Tablet should be used with caution in patients with liver disease. Dose adjustments may be required based on the severity of the condition. Please consult your doctor.
FAQs:
Q: How soon should I start taking PeP after exposure?
A: PeP is most effective when started within 2 hours and must be taken no later than 72 hours after exposure.
Q: Can I stop taking PeP if I feel fine?
A: No, you must complete the full 28-day course to ensure effectiveness.
Q: Can pregnant or breastfeeding women take Trilavir D PeP Tablet?
A: Consult a doctor before use; PeP is generally considered safe, but medical guidance is essential.
Q: What happens if PeP fails?
A: If PeP fails, further HIV testing and possible long-term ART will be necessary.
Related Lab Tests:
- HIV Test (before starting and after 4-6 weeks of completion).
- Liver and Kidney Function Tests (to monitor potential toxicity).
- Complete Blood Count (CBC) (to assess overall health).
Reviews
There are no reviews yet.